GEN Exclusives

More »

GEN News Highlights

More »
Mar 4, 2011

FDA Removes Liver Damage Warning from Gilead’s Pulmonary Arterial Hypertension Drug Label

  • A review of post-marketing data has led FDA to remove the liver damage warning from the prescribing information for Gilead Science’s pulmonary arterial hypertension (PAH) therapy Letairis® (ambrisentan 5 mg and 10 mg tablets). The once-daily drug has been approved in the U.S. since 2007 for helping to improve exercise ability and delay clinical worsening in PAH patients with WHO functional Class II-III symptoms. The label update means patients treated using Letairis will no longer need to undergo monthly liver function tests.

    The post-marketing data, collected through the Letairis Education and Access Program, reflected the use of ambrisentan over more than 7,800 patient years. Gilead says the data is consistent with results from the clinical trials used to support the drug’s registration. These 12-week controlled studies found the incidence of liver function abnormalities was 0% for Letrairis-treated patients and 2.3% among placebo-treated individuals.

    In its 2009 annual report Gilead suggested 200,000 people worldwide suffer from pulmonary arterial hypertension, and Letairis is used by one-third of patients receiving endothelin-receptor antagonist treatment. The firm reported Letairis sales of $64 million in the fourth quarter of 2010, up 23% on Q4 2009 figures. Sales for the 2010 year were up 31%, at $240.3 million.

Readers' Comments

Posted 03/04/2011 by Sonja Mindrebo

Yet another reminder to be cautious of prescription drug use.  THere are also dangers with over the counter medications like acetaminophen (Tylenol).  Neglecting to adhere to the recommended dosages could result in liver failure - - or even death.  Just another thought.  Regards, SK.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »